Oncological Treatment
We recommend
With Prof. Pavel Žák about Current Trends and Future Perspectives in Bone Marrow Transplantation and the Role of Carmustine in this Context
Hematopoietic stem cell transplantation has an indispensable place in the treatment of hemato-oncological diseases. We discuss current trends in this area, the significance and benefits of carmustine, the choice between BEAM and TEAM regimens, and the future of bone marrow transplantation in the context of new technologies with the head of the 4th Department of Hematology of the Faculty of Medicine, Charles University and University Hospital Hradec Králové, Prof. MUDr. Pavel Žák, Ph.D.
Prof. Miloš Broďák: Introduction of new drugs has significantly improved results even in progressive and recurrent prostate cancers
The prognosis and treatment outcomes for patients with various stages of prostate cancer have…
Use of Testosterone Level as a Biomarker for Quality of Life in Patients with Prostate Cancer
In the treatment of prostate cancer, in addition to surgical treatment, stereotactic body…
Articles on this topic
Benefit of Short-term Androgen-deprivation Therapy Added to Radiotherapy of Localized Prostate Cancer for Long-term Survival
Androgen-deprivation therapy is associated with several adverse effects that also affect…
Multimodal Treatment of Prostate Cancer in a Patient with Exceptionally Long Overall Survival − Case Report
A recently published case study by Romanian authors presents a rare instance of long-term…
Comparison of BEAM and TEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Lymphomas
At the beginning of this year, one of the few studies comparing the most commonly used…
Results of Long-Term Follow-Up of Patients with Prostate Adenocarcinoma After Radiotherapy with Short-Term Androgen Deprivation
Adding short-term androgen deprivation to radiotherapy improved overall survival,…
Impact of the combination of bevacizumab with erlotinib in patients with NSCLC and EGFR mutation on overall survival and time to disease progression
Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth…
What Can We Expect from Sorafenib in the Treatment of Liver Cancer Affected by Nonalcoholic Fatty Liver Disease?
Ubiquitous and increasingly common obesity is a risk factor for many cancers. Over the past 20…
Nearly 20 Years with Bevacizumab Has Brought Hope for Patients and Deeper Understanding of Solid Tumors
Bevacizumab is among the first targeted therapies used in oncology. For many indications where…
Erlotinib in Conditions of Routine Clinical Practice
The patient population in clinical trials is always somewhat selected. Only a well-conducted…
Safety of Long-Term Therapy with Bevacizumab in Oncological Patients
The angiogenesis inhibitor bevacizumab is typically administered long-term. Therefore, a study…
Prim. Pavel Jindra: Biosimilars are an accessible and effective treatment modality in hematooncology
“Based on our experience so far, biosimilars represent an effective and safe alternative to…
1
2
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- Prof. Miloš Broďák: Introduction of new drugs has significantly improved results even in progressive and recurrent prostate cancers
- Protection of Ovarian Function During Breast Cancer Treatment
- Use of Testosterone Level as a Biomarker for Quality of Life in Patients with Prostate Cancer
- With Prof. Pavel Žák about Current Trends and Future Perspectives in Bone Marrow Transplantation and the Role of Carmustine in this Context
- Biosimilar Drugs in Oncology
- Multimodal Treatment of Prostate Cancer in a Patient with Exceptionally Long Overall Survival − Case Report
Journal on this topic
Related topic
Interesting links